๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Not yet open
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Severe Obesity
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Not yet open
A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.
NCT07039032Paroxysmal Atrial Fibrillation (PAF)
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Chengdu
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Active, closed
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
NCT07597733Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Sichuan Academy of Medical Sciences
Not applicable
76
Chengdu
2025-09-26
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Recruiting
A Single Ascending Dose of HRS-2162 in Healthy Subjects
NCT07195604Reversal of Neuromuscular Blockade
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
64
Chengdu
2025-09-25
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
Chengdu, Guangzhou
2025-09-24
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged โ‰ฅ40 to โ‰ค85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Xiamen
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chongqing, Dalian, Datong
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Baotou, Beijing, Changde, Changsha, Chengdu, Chongqing, Dalian, Foshan
2025-09-17
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
NCT07215650Generalized Myasthenia Gravis
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Recruiting
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
NCT07134998Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Shanghai, Chengdu
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Recruiting
Oxytocin and Human Defensive Responses in a Dynamic Situation
NCT07162584Healthy
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2025-09-13
Not yet open
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
NCT07131644Kaposiform Hemangioendothelioma
West China Hospital
Phase 2
120
Chengdu
2025-09-13
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911SLE - Systemic Lupus Erythematosus
CytoCares Inc
Phase 1
32
Chengdu
2025-09-11
Recruiting
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
NCT06753747Esophagus Cancer
West China Hospital
Phase 1/2
45
Chengdu
2025-09-10
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
By invitation
TAVR vs. SAVR Study of VitaFlow Libertyยฎ for Severe BAV Stenosis
NCT06597188Aortic Stenosis, Bicuspid Aortic Valve (BAV)
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Not applicable
452
Chengdu
2025-09-08
Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
West China Hospital
Phase 1
10
Chengdu
2025-09-04
Recruiting
Individual Differences in Cognitive Control Predict Real-time fMRI Neurofeedback Performance
NCT07211269Healthy
University of Electronic Science and Technology of China
Not applicable
40
Chengdu
2025-09-03
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Active, closed
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
NCT06969352Gliomas
Servier (Tianjin) Pharmaceutical Co. LTD.
Not applicable
62
Beijing, Qionghai, Chengdu
2025-09-02
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Not yet open
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
NCT07154108Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Sichuan University
Phase 1
40
Chengdu
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
We-INtervention Among Chinese HIV-serodiscordant Male Couples
NCT06639932HIV
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Not yet open
Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy
NCT07172087Colorectal Cancer
Sichuan Cancer Hospital and Research Institute
Not applicable
258
Chengdu
2025-09
Recruiting
Study of CM559 in Healthy Subjects
NCT07175506Healthy Subjects
Keymed Biosciences Co.Ltd
Phase 1
40
Chengdu
2025-09
Recruiting
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
NCT07140237Healthy Adult Male
University of Electronic Science and Technology of China
Phase EARLY_PHASE1
250
Chengdu
2025-09
Not yet open
A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology for the Treatment of Paroxysmal Atrial Fibrillation
NCT07036068Paroxysmal Atrial Fibrillation (PAF)
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Chengdu
2025-08-31
Recruiting
Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty๏ผˆTKA๏ผ‰
NCT07127042Total Knee Arthroplasty
ScinnoHub Pharmaceutical Co., Ltd.
Phase 2
270
Chengdu
2025-08-27
Active, closed
Milk Free From A1-Type ฮฒ-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
NCT06980376Healthy Pregnant Women
a2 Milk Company Ltd.
Not applicable
100
Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu
2025-08-25
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Not yet open
Lateral Positioning for Extubation After Adenotonsillectomy
NCT07108218Perioperative Respiratory Adverse Events, Adenoidectomy, Tonsillectomy, Children
Sichuan University
Not applicable
350
Chengdu
2025-08-20
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750CRC (Colorectal Cancer)
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Active, closed
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUSยฎ PLUS (Sichuan)
NCT07152353Solid Tumor, Adult
Ion Beam Applications
Not applicable
47
Chengdu
2025-08-19
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women
NCT07118085Healthy Postmenopausal Women
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
56
Chengdu
2025-08-18
By invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629TNBC
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Active, closed
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07108699Chronic Obstructive Pulmonary Disease (COPD)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
180
Chengdu
2025-08-13
Recruiting
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
NCT07032688Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
55
Chengdu
2025-08-11
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639Tuberculosis
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Recruiting
Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
NCT07147049Moderate to Severe Acute Postoperative Pain
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 2
72
Chengdu
2025-08-08
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
NCT06615596Atrial Fibrillation (AF)
China National Center for Cardiovascular Diseases
Phase EARLY_PHASE1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Recruiting
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
NCT07061704Esophageal Cancer
Sichuan University
Phase 1/2
40
Chengdu
2025-08-01
Not yet open
Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins
NCT07046286Varicose Veins of Lower Limb, Venous Insufficiency of Leg, Vascular Disease๏ผŒPeripheral
Chengdu University of Traditional Chinese Medicine
Not applicable
200
Chengdu
2025-08-01
Recruiting
Assessment of DOT Spectacles in Chinese Children Extension
NCT07008001Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Recruiting
Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
NCT07077356Hepatocellular Carcinoma (HCC)
West China Hospital
Phase 1
15
Chengdu
2025-08-01
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
NCT07076823Colorectal Cancer, SGLT-2 Inhibitor
West China Hospital
Phase 1
15
Chengdu
2025-07-31
Not yet open
Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
NCT07088744Gastric Cancer (Diagnosis), Gastric High-grade Intraepithelial Neoplasia, Gastric Low-grade Intraepithelial Neoplasia, Gastritis
Changhai Hospital
Observational
169
Nanning, Shenyang, Chengdu, Shanghai
2025-07-30
Not yet open
Efficacy and Safety of Contrast EUS-Guided Tissue Glue/Coil Devascularization vs. BRTO for Preventing Recurrent Gastric Variceal Bleeding
NCT07049146Gastric Varices Bleeding
West China Hospital
Not applicable
242
Chengdu
2025-07-30
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
Chengdu, Shanghai, Wuhan
2025-07-28
Recruiting
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
NCT07096882Non-Small Cell Lung Cancer
Cytocraft Biopharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-07-26
Recruiting
ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer
NCT07086638Radiation Dermatitis
West China Hospital
Not applicable
5
Chengdu
2025-07-25
Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
NCT06918834Myelodysplastic Syndromes
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
236
Beijin, Zhengzhou, Jinan, Chengdu, Shijia Zhuang
2025-07-24
Recruiting
ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer
NCT07081074Radiation Dermatitis
West China Hospital
Not applicable
40
Chengdu
2025-07-23
Not yet open
Microscopic Varicocele Bypass Versus Ligation
NCT07065695Varicocele
Ke Dou
Not applicable
284
Chengdu
2025-07-22
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Not yet open
Inverted-ฮฉ Anastomosis in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central Pancreatectomy
NCT07087392Pancreatic Cystic Neoplasms
West China Hospital
Not applicable
20
Chengdu
2025-07-20
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
NCT07067346Neuroblastoma
Sichuan University
Phase EARLY_PHASE1
10
Chengdu
2025-07-18
Recruiting
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
NCT07011056Recurrent and Refractory Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
390
Chengdu
2025-07-18
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Active, closed
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
NCT06963710Chronic Hepatitis B Infection
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Recruiting
Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer
NCT07064577Radiation Dermatitis
West China Hospital
Not applicable
30
Chengdu
2025-07-15
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
NCT07059221Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
210
Chongqing, Chengdu
2025-07-11
Recruiting
Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World
NCT07105631Colorectal Cancer
West China Hospital
Observational
300
Chengdu
2025-07-10
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2025-07-09
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Not yet open
Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients
NCT06821633Diabetic Retinopathy
Sichuan Provincial People's Hospital
Not applicable
30
Chengdu
2025-07-07
Active, closed
Trametinib Treatment for Complicated Vascular Anomalies
NCT07072403Vascular Anomalies
West China Hospital
Phase 1/2
20
Chengdu
2025-07-07
Recruiting
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage โ…กA-โ…ขB Non-small Cell Lung Cancer
NCT06877299Lung Cancer, Non-small Cell Lung Cancer
Sichuan University
Phase 2
30
Chengdu
2025-07-04
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Active, closed
18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC
NCT07449858Non Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Not yet open
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484Lung Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
Not applicable
600
Chengdu
2025-07
Rows per page Showing 401–500 of 1291
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.